TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36036087

Group type: EXPERIMENTAL
Intervention: Low-dose vonoprazan-amoxicillin dual therapy (amoxicillin 1 g b.i.d. for 7 or 10 days, vonoprazan 20 mg b.i.d.)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: High-dose vonoprazan-amoxicillin dual therapy (amoxicillin 1 g t.i.d. for 7 or 10 days, vonoprazan 20 mg b.i.d.)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori-positive patients (L-VA and H-VA groups)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Helicobacter pylori-negative patients (normal controls)
Number of subjects: 41
Study: 33565987

Group type: EXPERIMENTAL
Intervention: AMIS‐PPSHI scale (12 items)
Number of subjects: 1375

Group type: EXPERIMENTAL
Intervention: Sexual health engagement and awareness subscale
Number of subjects: 1375

Group type: EXPERIMENTAL
Intervention: Enhancing dyadic communication subscale
Number of subjects: 1375

Group type: EXPERIMENTAL
Intervention: Managing sexual health care subscale
Number of subjects: 1375

Group type: EXPERIMENTAL
Intervention: 3-factor PPSHI structure
Number of subjects: 1375
Study: 32239541

Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 1660
Study: 33933206

Group type: EXPERIMENTAL
Intervention: Tocilizumab (400 mg–800 mg IV, depending on weight) plus usual standard of care
Number of subjects: 4116

Group type: COMPARATOR
Intervention: Usual standard of care
Number of subjects: 4116
Study: 33069063

Group type: COMPARATOR
Intervention: Ultrasound measurement of the transversus abdominis muscle during abdominal hollowing
Number of subjects: 20
Study: 32564957

Group type: EXPERIMENTAL
Intervention: Local anesthetic (lidocaine)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 24
Study: 33176205

Group type: EXPERIMENTAL
Intervention: Typhoid Conjugate Vaccine (TCV) plus control vaccine (inactivated polio vaccine) and MCV-A 28 days later
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Typhoid Conjugate Vaccine (TCV) and MCV-A
Number of subjects: 150

Group type: COMPARATOR
Intervention: Meningococcal Conjugate Vaccine (MCV-A) and control vaccine (inactivated polio vaccine)
Number of subjects: 150
Study: 32279703

Group type: EXPERIMENTAL
Intervention: Checking‐in
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Camping‐out
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 91
Study: 34331162

Group type: EXPERIMENTAL
Intervention: bALND (breast axillary lymph node dissection)
Number of subjects: 832

Group type: COMPARATOR
Intervention: sALND (standard axillary lymph node dissection)
Number of subjects: 832

Group type: EXPERIMENTAL
Intervention: bALND
Number of subjects: 832

Group type: COMPARATOR
Intervention: sALND
Number of subjects: 832
Study: 33351885

Group type: EXPERIMENTAL
Intervention: Genetic mimicry of ANGPTL4 inhibition
Number of subjects: 61240

Group type: EXPERIMENTAL
Intervention: Genetic mimicry of LPL enhancement
Number of subjects: 61240

Group type: EXPERIMENTAL
Intervention: Genetic mimicry of ANGPTL3 inhibition
Number of subjects: 61240

Group type: EXPERIMENTAL
Intervention: Genetic mimicry of ANGPTL4 inhibition and LPL enhancement
Number of subjects: 61240

Group type: EXPERIMENTAL
Intervention: Genetic mimicry of ANGPTL3
Number of subjects: 61240
Study: 35378069

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 33990500

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy
Number of subjects: 253

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 253
Study: 32861214

Group type: EXPERIMENTAL
Intervention: WSH interventions
Number of subjects: 1411

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1411
Study: 35544387

Group type: EXPERIMENTAL
Intervention: Oral lenacapavir for 14 days followed by subcutaneous lenacapavir every 6 months with optimized background therapy (Cohort 1)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Subcutaneous lenacapavir every 6 months with optimized background therapy (Cohort 2)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo for 14 days followed by oral lenacapavir and then subcutaneous lenacapavir with optimized background therapy (Cohort 1)
Number of subjects: 72
Study: 32142135

Group type: EXPERIMENTAL
Intervention: Action Observation (AO)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Action Observation + Motor Imagery (AO+MI)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo Observation (PO)
Number of subjects: 24
Study: 34171877

Group type: EXPERIMENTAL
Intervention: Checklist
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Global Rating Scale (GRS)
Number of subjects: 103
Study: 34408060

Group type: EXPERIMENTAL
Intervention: Open-label placebo (OLP) treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional OLP rationale
Number of subjects: 30
Study: 33226999

Group type: EXPERIMENTAL
Intervention: Protease inhibitor
Number of subjects: 263

Group type: COMPARATOR
Intervention: Non-nucleoside reverse transcriptase inhibitor
Number of subjects: 263

Group type: COMPARATOR
Intervention: Protease inhibitor vs. Non-nucleoside reverse transcriptase inhibitor
Number of subjects: 263
Study: 34872717

Group type: EXPERIMENTAL
Intervention: Intravenous iron (ferric carboxymaltose 1000 mg i.v.)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 98
Study: 33563165

Group type: EXPERIMENTAL
Intervention: Cyberspace-based education for one month
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 86
Study: 32346280

Group type: EXPERIMENTAL
Intervention: Black stroke survivors
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Aging, being female, being Black, and longer time since stroke
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Comorbidities
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Black race
Number of subjects: 1002
Study: 33503074

Group type: EXPERIMENTAL
Intervention: ART (antiretroviral therapy)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Older age at ART initiation (age 5–9 years)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Older age at ART initiation (age 10–14 years)
Number of subjects: 300
Study: 34210290

Group type: EXPERIMENTAL
Intervention: Continue anti-PD-1 treatment until disease progression/unacceptable toxicity/for at least 2 years in the absence of disease progression/unacceptable toxicity
Number of subjects: 1208

Group type: COMPARATOR
Intervention: Stop treatment
Number of subjects: 1208

Group type: EXPERIMENTAL
Intervention: Continue anti-PD-1 treatment
Number of subjects: 1208
Study: 32969024

Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT) for patients arriving between 6 and 24 hours with ASPECTS ≥7
Number of subjects: 56

Group type: COMPARATOR
Intervention: Endovascular treatment (EVT) for patients arriving between 0 and 6 hours
Number of subjects: 56
Study: 33028352

Group type: EXPERIMENTAL
Intervention: Intermittent calorie restriction (ICR) - a very low‐calorie diet during 3 days of the week for 8 weeks
Number of subjects: 88

Group type: COMPARATOR
Intervention: Continuous calorie restriction (CCR) - for 8 weeks
Number of subjects: 88
Study: 35294623

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 21300

Group type: COMPARATOR
Intervention: Vitamin K antagonists (VKAs)
Number of subjects: 21300
Study: 33612706

Group type: EXPERIMENTAL
Intervention: Genetically determined hs-CRP using IVCRP
Number of subjects: 10521

Group type: EXPERIMENTAL
Intervention: Genetically determined hs-CRP using IVAsian
Number of subjects: 10521

Group type: EXPERIMENTAL
Intervention: MR-Egger method for IVCRP
Number of subjects: 10521

Group type: EXPERIMENTAL
Intervention: MR-Egger method for IVAsian
Number of subjects: 10521
Study: 33095798

Group type: EXPERIMENTAL
Intervention: E-Cigarette (EC) arm; received an EC starter kit and 4-weeks supply of e-liquid
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual Care (UC) arm; received advice to quit and signposting to the local Stop Smoking Service
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both EC and UC arms
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: E-Cigarette (EC) arm
Number of subjects: 80
Study: 35984327

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA) measured through Global Physical Activity Questionnaire (GPAQ) and wearable activity data.
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA) measured through Previous Day Physical Activity Recalls (PDPAR).
Number of subjects: 66
Study: 34438103

Group type: EXPERIMENTAL
Intervention: Intranasal corticosteroids (INCS)
Number of subjects: 72147
Study: 35403447

Group type: EXPERIMENTAL
Intervention: Cabozantinib 60 mg/day tablet
Number of subjects: 247

Group type: COMPARATOR
Intervention: Cabozantinib 140 mg/day capsules
Number of subjects: 247
Study: 33009719

Group type: EXPERIMENTAL
Intervention: EyeSi Surgical Simulator proficiency test
Number of subjects: 23
Study: 32764830

Group type: EXPERIMENTAL
Intervention: Transmitters sharing their feelings with receivers
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Receivers communicating with other group members
Number of subjects: 158
Study: 34289471

Group type: EXPERIMENTAL
Intervention: High UFNET rate (>1.75 mL/kg/h)
Number of subjects: 1433

Group type: EXPERIMENTAL
Intervention: Middle UFNET rate (1.01‐1.75 mL/kg/h)
Number of subjects: 1433

Group type: EXPERIMENTAL
Intervention: Low UFNET rate (<1.01 mL/kg/h)
Number of subjects: 1433

Group type: COMPARATOR
Intervention: Higher UFNET rate tertile compared with middle tertile
Number of subjects: 1433

Group type: COMPARATOR
Intervention: Higher UFNET rate tertile compared with lower tertile
Number of subjects: 1433

Group type: EXPERIMENTAL
Intervention: Every 1.0 mL/kg/h increase in UFNET rate
Number of subjects: 1433

Group type: EXPERIMENTAL
Intervention: Longitudinal increases in UFNET rates
Number of subjects: 1433

Group type: EXPERIMENTAL
Intervention: UFNET rates >1.75 mL/kg/h compared with rates 1.01‐1.75 and <1.01 mL/kg/h
Number of subjects: 1433
Study: 33075715

Group type: EXPERIMENTAL
Intervention: Classification methods for diagnostic support through peripheral blood smear images of red blood cells.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Feature extraction methods and machine learning methods for classifying morphology.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized and Grid search for parameter optimization.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selection of important features for classification.
Number of subjects: 0
Study: 33956409

Group type: EXPERIMENTAL
Intervention: Fluoroscopy group (FG)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Nonfluoroscopy group (NFG)
Number of subjects: 120
Study: 32326304

Group type: EXPERIMENTAL
Intervention: Get Ready intervention (GR)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Usual care (CG)
Number of subjects: 31
Study: 35069783

Group type: EXPERIMENTAL
Intervention: 64-slice spiral CT images based on the DLEM algorithm
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional 64-slice spiral CT images
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 64-slice spiral CT images based on the DLEM algorithm (after processing)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 64-slice spiral CT images based on the DLEM algorithm (before processing)
Number of subjects: 120
Study: 32969962

Group type: EXPERIMENTAL
Intervention: Open-label positive suggestions
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Closed-label positive suggestions
Number of subjects: 112

Group type: COMPARATOR
Intervention: Open-label negative suggestions
Number of subjects: 112

Group type: COMPARATOR
Intervention: Closed-label negative suggestions
Number of subjects: 112
Study: 32868938

Group type: EXPERIMENTAL
Intervention: Nordic walking
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standard general exercise programme
Number of subjects: 39
Study: 36214664

Group type: EXPERIMENTAL
Intervention: In-vehicle spatial-simultaneous distractions
Number of subjects: 27

Group type: COMPARATOR
Intervention: In-vehicle spatial-sequential distractions
Number of subjects: 27
Study: 34492291

Group type: EXPERIMENTAL
Intervention: pMDI+VMN+Combihaler
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: VMN
Number of subjects: 24

Group type: COMPARATOR
Intervention: pMDI+T‐piece
Number of subjects: 24
Study: 35939578

Group type: EXPERIMENTAL
Intervention: 50 mg litifilimab
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: 150 mg litifilimab
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: 450 mg litifilimab
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 33607609

Group type: EXPERIMENTAL
Intervention: Nominal group technique sessions
Number of subjects: 79
Study: 35144164

Group type: EXPERIMENTAL
Intervention: Video-recorded lecture
Number of subjects: 160

Group type: COMPARATOR
Intervention: Live lecture
Number of subjects: 160
Study: 33705665

Group type: EXPERIMENTAL
Intervention: MV130
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 32279106

Group type: EXPERIMENTAL
Intervention: Endoscopic transtympanic myringoplasty (ETM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Endoscopic type I tympanoplasty (ETT)
Number of subjects: 40
Study: 35354635

Group type: EXPERIMENTAL
Intervention: GelStix nucleus augmentation device
Number of subjects: 72

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 72
Study: 35747962

Group type: EXPERIMENTAL
Intervention: Radiotherapy plus 80 mg/day nano-curcumin capsules
Number of subjects: 42

Group type: COMPARATOR
Intervention: Radiotherapy plus placebo
Number of subjects: 42
Study: 32912725

Group type: EXPERIMENTAL
Intervention: 80 mg of aspirin
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: 160 mg of aspirin
Number of subjects: 107
Study: 36195055

Group type: EXPERIMENTAL
Intervention: Online CRC risk calculator with risk-based recommendations
Number of subjects: 1495

Group type: COMPARATOR
Intervention: Usual care group (UCG)
Number of subjects: 1495
Study: 36162889

Group type: EXPERIMENTAL
Intervention: Laser acupuncture on PC6 and CV24 acupuncture points (0.8 J, 4 seconds, energy density 2.854 J/cm2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Laser acupuncture on PC6 and CV24 acupuncture points
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (sham treatment)
Number of subjects: 30
Study: 32087357

Group type: EXPERIMENTAL
Intervention: Antibacterial-eluting envelope (TYRX Absorbable Antibacterial Envelope)
Number of subjects: 6800

Group type: COMPARATOR
Intervention: Control group (no envelope)
Number of subjects: 6800
Study: 35481691

Group type: EXPERIMENTAL
Intervention: Auricular transcutaneous vagal nerve stimulation (10 minutes each side)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham stimulation (10 minutes each side)
Number of subjects: 16
Study: 33906292

Group type: EXPERIMENTAL
Intervention: Immunohistochemical expression of RET in cancer samples
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal control (adjacent tumor-free section)
Number of subjects: 60
Study: 35231057

Group type: EXPERIMENTAL
Intervention: Compassionate Mind Training program for Teachers (CMT‐T)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Waitlist control group (WLC)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: CMT‐T
Number of subjects: 155
Study: 34858175

Group type: EXPERIMENTAL
Intervention: Red Ginseng (RG) - 3 g/d for 12 weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 35833523

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short-term interventions to prevent diabetes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Therapeutic interventions at the time of prediabetes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prediabetes
Number of subjects: 0
Study: 34487647

Group type: EXPERIMENTAL
Intervention: Azithromycin plus Levamisole
Number of subjects: 118

Group type: COMPARATOR
Intervention: Azithromycin alone
Number of subjects: 118
Study: 32028085

Group type: EXPERIMENTAL
Intervention: Focused ultrasound (FUS) treatment
Number of subjects: 0
Study: 35168840

Group type: EXPERIMENTAL
Intervention: Willingness to get vaccinated
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Concerns about COVID-19 vaccine development and mistrust in vaccines
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Loss of employment due to COVID-19
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Loss of household income due to COVID-19
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Inability to pay bills and buy food due to COVID-19
Number of subjects: 172
Study: 34772437

Group type: EXPERIMENTAL
Intervention: Minimally invasive strategy (CARS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional strategy (FDI)
Number of subjects: 0
Study: 32779057

Group type: EXPERIMENTAL
Intervention: SZC 5 g
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: SZC 10 g
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 35378692

Group type: EXPERIMENTAL
Intervention: Consistent sequence of objects and locations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized sequence of objects and locations
Number of subjects: 0
Study: 33538655

Group type: EXPERIMENTAL
Intervention: IL-6
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: IL-8
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: CRP
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: IL-6 and CRP
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: IL-1β
Number of subjects: 680
Study: 32222367

Group type: EXPERIMENTAL
Intervention: PVP-I/DEX
Number of subjects: 753

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 753

Group type: EXPERIMENTAL
Intervention: PVP-I
Number of subjects: 753
Study: 35286606

Group type: EXPERIMENTAL
Intervention: E. faecalis lotion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vehicle lotion (control)
Number of subjects: 20
Study: 32439823

Group type: EXPERIMENTAL
Intervention: Oral insulin treatment
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 35641125

Group type: EXPERIMENTAL
Intervention: Prednisolone 5 mg/day
Number of subjects: 451

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 451
Study: 32524293

Group type: EXPERIMENTAL
Intervention: RDI < 70%
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: CCI ≥ 2
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: CCI < 2 and RDI ≥ 70%
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: CCI ≥ 2 and RDI < 70%
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Elderly DLBCL patients (65 years <) with RDI < 70%
Number of subjects: 211
Study: 33084095

Group type: EXPERIMENTAL
Intervention: Charcot foot group
Number of subjects: 20

Group type: COMPARATOR
Intervention: non‐Charcot foot group
Number of subjects: 20
Study: 32487088

Group type: EXPERIMENTAL
Intervention: Barriers to health care access for individuals with disabilities
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Attitudinal factors
Number of subjects: 12
Study: 36164769

Group type: EXPERIMENTAL
Intervention: Natural language processing (NLP) methods using bidirectional encoder representations from transformers
Number of subjects: 39

Group type: COMPARATOR
Intervention: Clinical raters
Number of subjects: 39
Study: 34448273

Group type: EXPERIMENTAL
Intervention: TAC monotherapy (Tacrolimus only after tapering Mycophenolate mofetil)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dual therapy (Tacrolimus and Mycophenolate mofetil)
Number of subjects: 0
Study: 32447575

Group type: EXPERIMENTAL
Intervention: Novel strength training (NST) involving eccentric overloaded strength training and neuromuscular electrical stimulation (NMES)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional strength training (CST) involving dynamic resistance exercises matched for training volume
Number of subjects: 22
Study: 35700440

Group type: EXPERIMENTAL
Intervention: Burosumab
Number of subjects: 4

Group type: COMPARATOR
Intervention: Orthopedic surgery
Number of subjects: 4
Study: 33603019

Group type: EXPERIMENTAL
Intervention: K‐prototypes clustering method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Kamila algorithm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Latent Class Model (LCM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Partitioning Around Medoids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hierarchical Clustering
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Latent Class Analysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gower distance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unsupervised Extra Trees dissimilarity
Number of subjects: 0
Study: 32148225

Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV) with helmet
Number of subjects: 26
Study: 35102797

Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best medical management (BMM)
Number of subjects: 0
Study: 32398633

Group type: COMPARATOR
Intervention: C90 (80% of 1 repetition maximum, mean velocity dropped to 90%)
Number of subjects: 11

Group type: COMPARATOR
Intervention: C70 (80% of 1 repetition maximum, mean velocity dropped to 70%)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (no bench press performed)
Number of subjects: 11
Study: 35255530

Group type: COMPARATOR
Intervention: Esketamine 0 mg/kg
Number of subjects: 92

Group type: COMPARATOR
Intervention: Esketamine 0.25 mg/kg
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Esketamine 0.5 mg/kg
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Esketamine 1 mg/kg
Number of subjects: 92
Study: 32940090

Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tuberculosis vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 vaccines (various candidates)
Number of subjects: 0
Study: 35130354

Group type: EXPERIMENTAL
Intervention: Managing Emotions Group (MEG) - an eight-session DBT-informed skills group
Number of subjects: 48
Study: 33706066

Group type: EXPERIMENTAL
Intervention: Thai Yoga (TY)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 22